Spectroscopic investigation of the interaction of water-soluble azocalix[4]arenes with bovine serum albumin

Interaction of piroxicam with bovine serum albumin investigated by spectroscopic, calorimetric and computational molecular methods

The binding of drugs to serum proteins is governed by weak non-covalent forces. In this study, the nature and magnitude of the interactions between piroxicam (PRX) and bovine serum albumin (BSA) was assessed using spectroscopic, calorimetric and computational molecular methods. The fluorescence data revealed an atypical behavior during PRX and BSA interaction. The quenching process of tryptophan (Trp) by PRX is a dual one (approximately equal static and dynamic quenched components). The FRET results indicate that a non-radiative transfer of energy occurred. The association constant and the number of binding sites indicate moderate PRX and BSA binding. The competitive binding study indicates that PRX is bound to site I from the hydrophobic pocket of subdomain IIA of BSA. The synchronous spectra showed that the microenvironment around the BSA fluorophores and protein conformation do not change considerably. The Trp lifetimes revealed that PRX mainly quenches the fluorescence of Trp-213 situated in the hydrophobic domain. The CD and DSC investigation show that addition of PRX stabilizes the protein structure. ITC results revealed that BSA-PRX binding involves a combination of electrostatic, hydrophobic and hydrogen interactions. The analysis of the computational data is consistent with the experimental results. This thorough investigation of the PRX-BSA binding may provide support for other studies concerning moderate affinity drugs with serum protein.Communicated by Ramaswamy H. Sarma.

A Chalcone-Based Potential Therapeutic Small Molecule That Binds to Subdomain IIA in HSA Precisely Controls the Rotamerization of Trp-214

The principal intent of this work is to explore whether the site-specific binding of a newly synthesized quinoline-appended anthracenyl chalcone, (E)-3-(anthracen-10-yl)-1-(6,8-dibromo-2-methylquinolin-3-yl)prop-2-en-1-one (ADMQ), with an extracellular protein of the human circulatory system, human serum albumin (HSA), can control the rotamerization of its sole tryptophan residue, Trp-214. With this aim, we have systematically studied the binding affinity, interactions, and localization pattern of the title compound inside the specific binding domain of the transport protein and any conformation alteration caused therein. Multiple spectroscopic experiments substantiated by an in silico molecular modeling exercise provide evidence for the binding of the guest ADMQ in the hydrophobic domain of HSA, which is primarily constituted by residues Trp-214, Arg-218, Arg-222, Asp-451, and Tyr-452. Rotationally restricted ADMQ prefers to reside in Sudlow site I (subdomain IIA) of HSA in close proximity (2.45 nm) to the intrinsic fluorophore Trp-214 and is interestingly found to control its vital rotamerization process. The driving force for this rotational interconversion is predominantly found to be governed by the direct interaction of ADMQ with Trp-214. However, the role of induced conformational perturbation in the biomacromolecule itself upon ADMQ adoption cannot be ruled out completely, as indicated by circular dichroism, 3D fluorescence, root-mean-square deviation, root-mean-square fluctuation, and secondary structure element observations. The comprehensive spectroscopic study outlined herein provides important information on the biophysical interaction of a chalcone-based potential therapeutic candidate with a carrier protein, exemplifying its utility in having a regulatory effect on the microconformations of Trp-214.